It is widely believed that tau stabilizes microtubules in the axon [1] [2] [3] and, hence, that disease-induced loss of tau from axonal microtubules leads to their destabilization [3] [4] [5] . An individual microtubule in the axon has a stable domain and a labile domain [6] [7] [8] . We found that tau is more abundant on the labile domain, which is inconsistent with tau's proposed role as a microtubule stabilizer. When tau is experimentally depleted from cultured rat neurons, the labile microtubule mass of the axon drops considerably, the remaining labile microtubule mass becomes less labile, and the stable microtubule mass increases. MAP6 (also called stable tubule-only polypeptide), which is normally enriched on the stable domain [9] , acquires a broader distribution across the microtubule when tau is depleted, providing a potential explanation for the increase in stable microtubule mass. When MAP6 is depleted, the labile microtubule mass becomes even more labile, indicating that, unlike tau, MAP6 is a genuine stabilizer of axonal microtubules. We conclude that tau is not a stabilizer of axonal microtubules but is enriched on the labile domain of the microtubule to promote its assembly while limiting the binding to it of genuine stabilizers, such as MAP6. This enables the labile domain to achieve great lengths without being stabilized. These conclusions are contrary to tau dogma.
In Brief Qiang, Sun, et al. show that cultured rat neurons depleted of tau undergo microtubule loss that is not explicable on the basis of microtubule destabilization. Rather, the loss is due to the diminution of the labile domains of microtubules, indicating that tau's actual role in the axon is to allow microtubules to have long labile domains.
SUMMARY
It is widely believed that tau stabilizes microtubules in the axon [1] [2] [3] and, hence, that disease-induced loss of tau from axonal microtubules leads to their destabilization [3] [4] [5] . An individual microtubule in the axon has a stable domain and a labile domain [6] [7] [8] . We found that tau is more abundant on the labile domain, which is inconsistent with tau's proposed role as a microtubule stabilizer. When tau is experimentally depleted from cultured rat neurons, the labile microtubule mass of the axon drops considerably, the remaining labile microtubule mass becomes less labile, and the stable microtubule mass increases. MAP6 (also called stable tubule-only polypeptide), which is normally enriched on the stable domain [9] , acquires a broader distribution across the microtubule when tau is depleted, providing a potential explanation for the increase in stable microtubule mass. When MAP6 is depleted, the labile microtubule mass becomes even more labile, indicating that, unlike tau, MAP6 is a genuine stabilizer of axonal microtubules. We conclude that tau is not a stabilizer of axonal microtubules but is enriched on the labile domain of the microtubule to promote its assembly while limiting the binding to it of genuine stabilizers, such as MAP6. This enables the labile domain to achieve great lengths without being stabilized. These conclusions are contrary to tau dogma.
RESULTS AND DISCUSSION

Tau Depletion Causes Preferential Loss of the Labile Microtubule Fraction in the Axon
An early indication that tau may not be responsible for the stability of axonal microtubules was reported almost twenty years ago, when cultured neurons were microinjected with a tau antibody prior to axon outgrowth. In that study, axons free of tau (which was trapped in the cell body) were then allowed to grow for a few hours, and these axons contained microtubules that were no less stable than controls [10] . Here, we delved deeper into the issue by comparing microtubule levels in the axons of cultured rat neurons after four days of tau depletion by RNAi. Unlike those earlier studies, which were only performed on cultured rat sympathetic neurons from the superior cervical ganglia (SCG), our studies were conducted on both rat cortical neurons and SCG neurons (with similar results obtained with both types of neurons). For this, we used small interfering RNA (siRNA) introduced by nucleofection, which results in transfection of over 90% of the neurons in these cultures [11] . Depletion of tau over those four days was confirmed by western blot, with most of the tau depleted by the second day and no restoration in tau levels by the fourth day ( Figure 1A ). On the fourth day, cultures were prepared for various microtubule-related analyses. As in previous studies using this approach on rat brain neurons [12] [13] [14] , there was no obvious change in axon length or morphology with tau depletion with either type of neuron, except that branching frequency was slightly higher in tau-depleted axons of cortical neurons. Microtubule levels were assessed by quantitative immunofluorescence, comparing axons of neurons into which we introduced control siRNA or tau siRNA. Per unit length, the axons of tau-depleted cortical neurons displayed roughly 25% less microtubule mass than their control counterparts ( Figures 1B and 1C) , and roughly the same was true of SCG neurons (data not shown).
We next wished to investigate whether the microtubule loss due to tau depletion is chiefly of the stable domains of the axonal microtubules or their labile domains. For this, we exploited previous findings that the labile domains of axonal microtubules have much higher levels of tyrosinated tubulin than the stable domains [6] [7] [8] . Detyrosination is a post-translational modification of alpha tubulin that accumulates in the microtubule over time and hence becomes concentrated in the stable domain, although it is also present at lower levels in the labile domain [7, 15] . Levels of tyrosinated or detyrosinated tubulin can also vary in the labile domain, reflecting differences in how labile a labile domain is, with very labile ones containing fewer detyrosinated subunits than less labile ones [16] . Conventional immunostaining revealed 25% higher levels of detyrosinated tubulin per unit length of axon (not just the percentage relative to total but the absolute amount) in tau-depleted axons compared to control axons ( Figures 1B  and 1D ).
To delve into this further, we prepared cultures for immunofluorescence double-label visualization of total tubulin and tyrosinated tubulin using an extraction and fixation protocol that causes microtubules to splay apart so that labile domains can be visualized in especially splayed regions along the axon's length [8] . (Particular care was taken to compare equally splayed regions, because the microtubule array along the tau-depleted axon was generally less compact than in control axons, consistent with a potential role for tau as a microtubule bundler; see Figures S1A and S1B.) The number of labile domains (DMSO: tau = 100% ± 14%, tyrosinated tubulin = 100% ± 9%, bIII-tubulin = 100% ± 12%, n = 27; nocodazole: tau = 31% ± 3%, tyrosinated tubulin = 8% ± 0.9%, bIII-tubulin = 45% ± 6%, n = 15.) (Q and R) Pie graphs represent quantification of data from the experiments on axons of cultured SCG neurons after nocodazole treatment for 15 min followed by washout and 3-5 min of recovery. (Q) The newly assembled microtubule staining profile that stained for tyrosinated tubulin, but not tau (+/À), or both tyrosinated tubulin and tau (+/+). (R) The tau staining profile that stained also for tyrosinated tubulin (+/+) or did not stain for tyrosinated tubulin (+/À). (S) Scatterplot represents the co-localization of tyrosinated tubulin and tau after nocodazole treatment 15 min with washout 5 min. Pearson's coefficient (p = 0.89) was calculated using ImageJ Coloc2 plugin. All of the error bars appearing in this figure stand for SEM. See also Figure S1 .
(i.e., microtubule profiles rich in tyrosinated tubulin) visualized in this fashion per unit length of axon was reduced in the taudepleted axons compared to control counterparts by 24% (Figures 1E and 1F) .
Taken together, these results indicate that tau depletion results in the net loss of microtubule mass from the axon and that the loss of microtubule mass is predominantly of the labile domains rather than the stable domains of the microtubules. In addition, there is an increase in microtubule stability in the remaining microtubule mass, relative to control, that is not explicable on the basis of the diminution of the labile domains. The increase in detyrosinated tubulin suggests either that the remaining portions of the labile domains are becoming less labile, the stable domains are becoming more stable, or both.
For a rescue experiment, GFP-tagged full-length tau (human tau sequence, not affected by siRNA to rat tau sequence) was expressed in rat cortical neurons that had been depleted of tau in order to ascertain whether the stability properties of the microtubules were restored to normal. We did this to confirm the specificity of the siRNA but also because a number of previous studies have shown that ectopically expressing tau in non-neuronal cells results in greater microtubule stability [14, [17] [18] [19] , whereas our expectation is that restoration of tau to tau-depleted neurons should result in a decrease of microtubule stability ( Figure 1B) . Consistent with our expectation, restoration of tau to control levels resulted in a decrease in the levels of detyrosinated tubulin back to control levels and an increase in total microtubule levels back to control levels ( Figures 1C and 1D ). These results confirm the specificity of the siRNA and also suggest that previously published results on ectopic tau expression in non-neuronal cells showing enhanced microtubule stability do not reflect the actual role of tau in the axon.
Tau Is Enriched on Labile Domains of Axonal Microtubule Relative to Stable Domains
The distribution of tau in growing axons is another hint, already in the literature, that tau's role in the axon is contrary to dogma. Specifically, tau is enriched in the distal region of the axon, where labile domains of microtubules are known to predominate [20, 21] . However, several other proteins also concentrate in the distal region of the axon [22] [23] [24] , so it remains unclear whether the distal enrichment of tau is a specialization of that region of the axon or a manifestation of tau's enrichment on labile domains of microtubules everywhere along the axon. In support of the latter, we found a high degree of correlation between tau staining and tyrosinated tubulin staining in the axons of both SCG (data not shown) and cortical neurons (Figures S1C and S1D). However, we could not use the splay technique to resolve the issue with finer resolution because the extraction procedure for that technique strips tau from the microtubules. Therefore, we used an indirect approach ( Figures 1G-1R ). We reasoned that if there is more tau on labile domains than stable domains, then after 15 min in nocodazole (a drug that binds free tubulin subunits, thus inducing microtubule depolymerization), the levels of microtubule-associated tau in the axon should display a greater decrease than the decrease in microtubule mass. Our sample preparation procedure was previously optimized to release as much of the free tau as possible without stripping tau from the microtubules [20, 25] , but to further optimize staining for only tau that is microtubule associated, we used the tau1 antibody, which recognizes tau that is not phosphorylated at sites that when phosphorylated induce detachment of the tau from the microtubule [26] [27] [28] . Similar results were obtained with generic tau antibodies, such as tauR1 and tau5 (data not shown).
Shown in Figure 1P are the results with SCG neurons. Similar results were obtained with cortical neurons (data not shown). After 15 min in drug, there was a 70% diminution of microtubule-associated tau, whereas there was only a 50% decrease in microtubule mass ( Figures 1H, 1K, 1N , and 1P). This suggests that 70% of the microtubule-associated tau in the axon is normally on the labile domains of the microtubules whereas only 30% is on the stable domains.
To pursue this further, we conducted an experiment in which the nocodazole was washed from the culture to permit microtubule reassembly. Microtubule reassembly occurs from the plus ends of the stable domains of microtubules that remain after the nocodazole treatment [29] . Reassembly was allowed to occur for just 3-5 min in order that the newly assembled labile domains remain relatively short, so that they appear as small segments in the axonal shaft in immunostain analyses of tyrosinated tubulin [29] . In experiments double labeling for tyrosinated tubulin and tau, we found a high degree of correlation between these fluorescent microtubule segments and tau immunoreactivity ( Figures 1I, 1L , 1O, and 1Q-1S), confirming that tau is concentrated on labile domains relative to stable domains.
Depletion of Either Tau or MAP6 Causes Changes in the Other
Despite a 25% reduction in total microtubule mass in taudepleted axons, there was a 25% increase in detyrosinated tubulin relative to control axons ( Figures 1B-1D ), suggesting that whatever protein(s) are stabilizing the stable domain of the microtubule take on a wider distribution along the microtubule mass of the axon in the absence of tau. Previously, it was reported that stable domains have more microtubule-associated protein 6 (MAP6) (also called stable tubule-only polypeptide) bound to them than labile domains [9] , prompting us to posit that MAP6 might be such a protein. Fortifying this speculation are studies on other cell types showing that MAP6 is mostly unbound to microtubules until the cells are treated with cold, after which significantly more MAP6 binds to the microtubules, thereby enhancing their stability [30] . In addition, biochemical studies indicate that MAP6 can diffuse or ''slide'' along the microtubule [31] , consistent with its potential to spread out along the microtubule after tau depletion and thereby increase the length of the stable domain relative to the entire microtubule. Finally, MAP6's ability to stabilize axonal microtubules has recently been confirmed by experimental studies on neurons [32] . Thus, MAP6 is an appealing possibility for a MAP that can affect microtubule stability by attaching and detaching to the microtubule or sliding along its length in response to other events that might occur, such as tau depletion.
Initially, we performed western blotting on the cortical cultures, which demonstrated that depletion of MAP6 significantly increased the levels of tau by 29%, whereas depletion of tau significantly increased the levels of MAP6 by 54% ( Figures  2A-2D ). We then ascertained whether depletion of either tau or MAP6 results in a change in the distribution of the other. Shown in Figure S1C are cortical neurons double labeled for immunofluorescence visualization of tyrosinated tubulin and microtubulebound tau. When MAP6 was depleted by siRNA, tau took on a more widespread distribution in the axon ( Figures S2A-S2I ). In the case of tau depletion, we focused on the distal region of the axon contiguous with the growth cone, which is especially rich in labile microtubule domains and normally enriched with microtubule-bound tau. Immunofluorescence double labeling (J) Co-localization quantification of MAP6 and microtubule immunostaining intensities in the growth cone (control, R = 23% ± 5% n = 10; tau siRNA, R = 53% ± 5% n = 10) using ImageJ and the Pearson's correlation coefficient is shown. **p < 0.01. (K-P) Immunofluorescence (inverted) image represents microtubule mass in the growth cone before and after nocodazole treatment for 10 min in control neurons (K and L), tau-depleted neurons (M and N), and MAP6-depleted neurons (O and P), respectively. The scale bar represents 20 mm. (Q) Bar graph represents microtubule mass quantification in the growth cone normalized to growth cone area, after nocodazole treatment for 10 min in control group, tau-depleted group, or MAP6-depleted group, respectively. (DMSO: control = 100% ± 14%, n = 20, tau siRNA = 107% ± 16%, n = 20, MAP6 siRNA = 98% ± 21%, n = 20; nocodazole: control = 47% ± 6%, n = 22, tau siRNA = 92% ± 8%, n = 22, MAP6 siRNA = 18% ± 4%, n = 23.) *p < 0.05; **p < 0.01. for tubulin and MAP6 indicates that these microtubules are normally deficient in MAP6. However, in the case of tau-depleted axons, the microtubules along the axon and the growth cone become rich in MAP6 (Figures 2E-2J ). This same phenomenon was observed in the lamellipodia that extend from the axonal shaft, into which microtubules splay (Figures S3A-S3D) . Thus, both the levels and distributions of these two proteins are intimately related.
At present, we do not know whether MAP6 is unique with regard to the present observations or whether other stabilizers of microtubules have a similar relationship with tau. We reasoned that doublecortin might be a likely candidate, because doublecortin is normally enriched in tau-deficient regions of the axon [25] and because tau redistributes to bind microtubules previously bound to doublecortin when doublecortin is depleted [25] . However, we found that microtubules do not become rich in doublecortin when tau is depleted ( Figures S4A-S4F ).
Depletion of MAP6 Has Roughly Opposite Effects on Microtubule Stability as Tau Depletion
To ascertain whether the growth cone microtubules of neurons depleted of tau were made more stable by MAP6 binding to them, we treated the cultures with nocodazole for just 10 min to deplete much of the labile microtubule mass while not causing notable axon retraction. We focused on stalled growth cones in the cortical neuronal cultures because they have a mixture of stable and labile microtubule domains, more similar to the axonal shaft than the growth cone of an elongating axon [33] . In control neurons, about 53% of the microtubule mass in stalled growth cones was lost as a result of the drug treatment ( Figures 2K,  2L , and 2Q). However, in the case of stalled growth cones of tau-depleted axons, almost none of the microtubule mass was lost ( Figures 2M, 2N , and 2Q), indicating that the microtubules had become more stable in the absence of tau. In the case of stalled growth cones of MAP6-depleted axons, about 80% of the microtubule mass was lost from the growth cone as a result of the nocodazole treatment ( Figures 2O-2Q) , consistent with MAP6 being a genuine stabilizer of microtubules in the axon. (All of the microtubule mass quantifications were normalized to the growth cone areas. Growth cones are smaller in MAP6-depleted neurons compared to control or tau-depleted neurons; Figures 2O, 2P , and 2R.)
We further pursued changes in microtubule stability upon the depletion of tau or MAP6, next focusing on the axonal shaft. In a parallel study to the one we performed on tau-depleted axons ( Figures 1C-1E) , we double labeled MAP6-depleted neurons for detyrosinated tubulin and bIII-tubulin. MAP6 depletion resulted in a 27% decrease in total microtubule mass per unit length of axon ( Figures 3A and 3B) , which is just slightly higher than the 25% decrease observed with tau depletion. However, unlike tau depletion, which resulted in a 25% increase in detyrosinated tubulin staining per unit length of axon, MAP6 depletion resulted in a 30% decrease (Figures 3A and 3C ). Western blots of cortical neuronal cultures depleted of either tau or MAP6, pre-extracted to release free tubulin, were entirely consistent with these immunofluorescence-based results (Figures 3D-3F) .
We pursued an additional set of studies to investigate whether tau depletion causes the labile domains of microtubules to become less labile and whether MAP6 depletion causes the labile domains to become more labile. Being more or less labile would mean more or less dynamic, as observed in live-cell imaging [15] . We examined neurons expressing GFP-labeled end-binding protein 3 (EB3), in which excursions of microtubule assembly display as movements of fluorescent ''comets'' [15] . Tau depletion substantially decreased the number of comets in the axon (Figures 3G-3I ). MAP6 depletion did not alter the number of comets, consistent with labile domains becoming longer than in controls, but not more numerous (Figures 3G and 3H) . With regard to comet velocity, tau depletion caused a decrease, whereas MAP6 depletion caused an increase ( Figures 3G and 3I) , which is consistent with the labile domains being less labile after tau depletion and more labile after MAP6 depletion.
The observation of notably fewer EB3 comets in the taudepleted axons is noteworthy in light of the fact that the stable domain is just as capable of elongating a new labile domain as a labile domain is of simply getting longer [29] . Theoretically, the tau-depleted axons and the control axons should have an equal number of EB3 comets unless the presence of tau is having an additional effect, namely to promote the assembly of the labile domain. The fact that this is not the case indicates that the labile domains are able to become long not only through tau's capacity to prevent them from being stabilized but also through tau's capacity to promote their elongation. This conclusion is consistent with how tau was initially viewed when it was discovered, namely as a promoter of microtubule assembly in the axon [34] .
The fact that expression levels of tau and MAP6 are negatively correlated instead of positively correlated seems contrary to their inverse effects on microtubule stability. We are interested in exploring this further, especially in light of the potential implications for disease if MAP6 is overexpressed in response to tauopathy.
Quantitative Analyses on Microtubule Fractions in the Axon Assessed by Rates of Drug-Induced Depolymerization In a final set of studies, we quantified the rates of microtubule disassembly induced by nocodazole. This strategy is based on the premise that nocodazole depolymerizes microtubules at rates reflective of the dynamic properties of the microtubules. For this, we used quantitative immunofluorescence to ascertain microtubule levels after various times in the drug, ranging from 5 to 60 min ( Figures 4A and 4B) . Previous studies established that most of the labile microtubule fraction of the axon depolymerizes by 15 min in nocodazole, whereas the stable fraction is diminished much more slowly over a period of hours [6, 7, 35, 36] . This manifests as a biphasic decay in microtubule mass when the data are graphed, with the first phase displaying a far sharper decline than the second phase. We previously reported that, in the case of SCG neurons, roughly 50% of the microtubule mass of the axon is labile and the other half is stable [6, 7] . Here, we show that, in the control axons of rat cortical neurons, roughly $64% of the microtubule mass is labile, while $36% is stable, whereas in tau-depleted axons (in which roughly a fourth of the microtubule mass is lost, relative to control), $38% of the microtubule mass is labile, while $62% is stable.
In addition, the decline of the first phase of the biphasic decay is less steep in the case of the tau-depleted axons compared to control axons, which is consistent with the labile domains of the microtubules being less labile (i.e., more stable) after tau depletion. In the case of MAP6-depleted axons, there is a 27% reduction in total microtubule mass, but the proportions of stable and labile are not obviously different from control. However, the decline of the first phase of the biphasic decay is steeper than controls, which is consistent with the labile domains being more labile after MAP6 depletion. These changes are remarkably consistent with the results observed with the EB3 comets. The decline of the second phase was not detectably different from controls in the case of either tau or MAP6 depletion, suggesting that stabilizers other than MAP6 are sufficient for the stable domain (while shorter in the absence of MAP6) to remain just as stable. A more detailed mathematical treatment of the data, including t 1/2 values for the phases of decay, is provided in the legend of Figure 4 .
These drug results combine with the other results presented here to indicate that (1) after tau or MAP6 depletion, there is a net loss of microtubule mass from the axon; (2) after tau depletion, the labile microtubule fraction is diminished whereas the stable fraction is increased; (3) after MAP6 depletion, both the labile and stable fractions are diminished; (4) these effects are best explained by changes in the length of the labile and stable microtubule domains; and (5) the labile domains are less labile after tau depletion but more labile after MAP6 depletion. These results, summarized in Figure 4C , are not consistent with the dogma that tau is responsible for stabilizing axonal microtubules but rather suggest that tau enables the labile domains to grow longer than they otherwise would, without being stabilized. By contrast, MAP6 is a genuine stabilizer of axonal microtubules that regulates the properties of the labile domain in a manner opposite to tau.
How tau outcompetes genuine stabilizers for the microtubule lattice is unknown, but a simple competition for the same binding site on the microtubule seems unlikely. Tau is known to come on and off the microtubule at rapid rates of milliseconds [37] , which may contribute to how it keeps genuine stabilizers from accessing the microtubule lattice. We posit that the means by which a labile domain or a portion of it becomes stabilized involves a signaling cascade that phosphorylates tau so that it detaches from the microtubule, thus allowing MAP6 and other stabilizing proteins to bind. Modifications of the stabilizing proteins may contribute as well [32] .
Concluding Remarks
Abundant data from test tube and overexpression studies indicate that tau has the capacity to stabilize microtubules [1, 17, 19, 38] , but whether it does so in the physiological context of the axon has undergone surprisingly little testing. There have been hints in the literature that tau is not a stabilizer of microtubules in the axon [10, 15, 20, 21, 37, 39] , but for the most part, these hints have not been pursued and have not impacted the field. Hundreds of research papers, websites, and instructional materials continue to describe tau as an important stabilizer of axonal microtubules [40, 41] , with this idea taken so seriously by the biomedical community [4, 5] that microtubule-stabilizing drugs have been in clinical trials for diseases for tau-based neurodegenerative diseases [42] . Based on our data, we posit that the real manner by which tau contributes to the stability properties of axonal microtubules is to permit them to have labile domains that can become long without being stabilized. Tau also promotes the elongation of the labile domains and thereby Here, we applied a previously published strategy [7, 15] to measure the t 1/2 and percentages of the two phases of microtubule decline in control, tau-depleted, or MAP6-depleted axons. Using this method, for control cortical axons, we calculated that the t 1/2 for the first phase was $5 min, whereas that for the second phase was $126 min. For tau-depleted axons, the t 1/2 for the first phase was $6 min, whereas that for the second phase was $124 min. For MAP6-depleted axons, the t 1/2 for the first phase was $1 min, whereas that for the second phase was $125 min. In control axons, 64% of the total microtubule mass comprises the first phase whereas 36% comprises the second phase. In taudepleted axons, 38% and 62% comprise these two phases, respectively, whereas, in MAP6-depleted axons, 59% and 41% comprise these two phases, respectively. Phase 1 and phase 2 do not perfectly represent the labile and stable microtubule fractions because, for that to be the case, the stable and the labile microtubule fractions would have to be equally accessible to depolymerization. Given that the labile domain of any given microtubule must depolymerize completely before the stable domain can start to depolymerize, the t 1/2 for the first phase in this mathematical analysis is not directly synonymous with the labile fraction, which would for these reasons becomes even less labile (i.e., more stable) after tau depletion than indicated by the comparison of phase 1 kinetics. (C) Schematic represents the role of tau and MAP6 in regulating the stable (shown in green) and labile (shown in shades of red) domains of axonal microtubules. The two domains of an individual microtubule differ markedly from one another in their stability properties. The labile domain can vary in how labile it is, with lighter red indicating less labile and darker red indicating more labile. Blue and yellow thread-like structures represent tau and MAP6, respectively. After tau depletion, there is loss of microtubule mass, with the microtubules in the axon having diminished labile domains but increased stable domains. After MAP6 depletion, there is loss of microtubule mass, but the proportions of stable and labile remain roughly similar to control. The labile domains are less labile after tau depletion but more labile after MAP6 depletion. We posit that an enrichment of tau on the labile domain prevents MAP6 and other genuine microtubule stabilizers from binding to the microtubule, thereby keeping the labile domain labile and allowing it to elongate without being stabilized.
supports the existence of a robust labile microtubule fraction in the axon throughout the life of the neuron.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter W. Baas (pwb22@drexel.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All of the primary neuronal cultures used in this study were generated from Sprague-Dawley (SD) rats purchased from Taconic (Rensselaer, NY). All of the experiments that included SD rats were approved by Drexel University Institutional Animal Care And Use Committee (IACUC) and all of the experiments conform to relevant regulatory standards. For primary neuronal cultures, fetuses/pups of both genders were used.
Cell cultures
Cortical neurons were dissected from frontal cerebral cortex of 19-day SD rat fetuses of both genders, and then cultured as previously described [12] . Superior cervical ganglia (SCG) were acquired from P0-P2 SD rat pups of both genders and cultured as previously described [10] . 
METHOD DETAILS Transfections
Control scrambled siRNA (Sigma, SIC001), tau siRNA (4 sequences of siRNAs of tau were combined for use; Sigma, SASI_Rn01_ 000548888, SASI_Rn01_00054889, SASI_Rn01_00054890 and SASI_Rn02_00261575) or MAP6 siRNA (3 sequences of siRNAs of MAP6 were combined for use; Sigma, SASI_Rn01_00121264, SASI_Rn01_00121265, SASI_Rn01_00121266) were delivered by nucleofection (Nucleofector TM 2b, Lonza) into neurons prior to plating using Nucleofector Kits for Rat Neurons (Lonza, VSPI-1003). For all nocodazole studies, experiments are done on the fourth day after plating. The GFP-EB3 experiments were conducted on the third day after plating. For all other experiments, the cells were cultured for 2-3 days (to allow for siRNA-targeted proteins to be depleted) on 35 mm diameter Petri dishes coated with 1 mg/ml poly-L-lysine (Sigma, P2636-25MG), and then re-plated for two days prior to experiments on glass-bottomed dishes (Cellvis, #D35-14-1.5-N) coated with 1 mg/ml poly-L-lysine.
Immunofluorescence
For most experiments, cultures were co-extracted and fixed for 10 minutes in a solution containing 4% paraformaldehyde, 1x PHEM buffer (PIPES, HEPES, EDTA, MgCl2), 0.2% glutaraldehyde, and 0.1%Triton X-100. Glutaraldehyde was then quenched by treatment of the cultures twice for 15 minutes each with 2 mg/mL sodium borohydride. Cultures were then blocked for 1 hour with normal goat serum (Jackson ImmunoResearch #005-000-121) and 10% bovine serum albumin (BSA) (Sigma#A7906-100G), followed by incubation with primary antibodies overnight at 4 C and then secondary antibodies for an hour at room temperature. For the nocodazolebased assay for measuring stable and labile microtubule fractions, the cultures were pre-extracted with a 0.05% Triton X-100 microtubule-stabilizing buffer [35] for 90 s (to release free tubulin), prior to fixation with the same fixation solution indicated above but without Triton X-100. For MAP6 immunostaining, cultures were fixed in ice-cold methanol for 8 minutes (without pre-extraction), followed by the same procedure as above, but without the sodium borohydride step.
Primary antibodies were: rabbit anti-bIII-tubulin (1:1500; Biolegend #802001), mouse anti-bIII-tubulin (1:1500; Biolegend #801202), rat anti-tyrosinated tubulin (1:1500; Millipore, MAB1864); rabbit anti-detyrosinated tubulin (1:1500; Millipore AB3201), mouse tau1 antibody (1:1000, Gift from Dr. Nicholas Kanaan at Michigan State University), rabbit anti-doublecortin (1:1000; Abcam, #ab18723), rabbit anti-MAP6 (1:800) [44] . Appropriate secondary antibodies were purchased from Jackson ImmunoResearch.
Microtubule splay assay
An immunofluorescence preparation procedure previously reported to splay apart the microtubules along the axonal shaft of SCG neurons [8] was modified for use on cortical neuron axons. For this, cortical neurons were re-plated on glass-bottomed dishes coated with 1 mg/ml Poly-L-lysine at a density of 8,000 cells per dish. The culture was washed once with warm 1x PBS and once 1x PHEM buffer (PIPES, HEPES, EDTA, MgCl2) and then exposed for 3 minutes to pre-extraction medium (1x PHEM buffer, 0.2% Triton X-100, protease inhibitors, 10 mM taxol (Cytoskeleton, #TXD01). The cells were then fixed for 10 minutes with the same fixation solution indicated above but without Triton X-100. Cells were stained for bIII-tubulin and tyrosinated tubulin, and various parameters were quantified using ImageJ and Zeiss blue edition software including number of individual microtubule profiles per 100 mm of the axon, percentage of the individual microtubule profiles double positive for bIII-tubulin and tyrosinated tubulin and average width of the axons.
Nocodazole-based assay for measuring stable and labile microtubule fractions Cultures were treated for 5, 15, 30 or 60 minutes with DMSO (control; vehicle used to dissolve nocodazole) or 2 mg/mL nocodazole (Sigma# M1404-2MG). Immediately following nocodazole treatment, cells were pre-extracted and prepared for immunofluorescence staining for bIII-tubulin as indicated above. Axons were traced using ImageJ and their intensities (averaged per unit length of axon) were plotted as percentage relative to control for various time points.
Nocodazole washout experiments
Cultures were treated for 15 minutes with nocodazole, and then the drug was washed out twice rapidly with culture medium, after which neurons were allowed to reassemble microtubules for 3-5 minutes. After preparation for immunofluorescence (see above), axons of neurons stained for tau, tyrosinated tubulin and bIII-tubulin were traced using ImageJ and their staining intensities were plotted as percentage between nocodazole-treated and DMSO-treated (i.e., vehicle alone). Co-localization of tyrosinated tubulin and tau were represented as a scatterplot using ImageJ Coloc2 plugin.
Rescue experiment
Control siRNA, tau siRNA or MAP6 siRNA was introduced into cortical neurons by electroporation as described above. 3 days later, cells were collected by using accutase (Stem cell Technology 07920), transfected with GFP-tau-4R (human sequence [45] ; gift from Dr. Gloria Lee from the University of Iowa), by electroporation and re-plated on glass bottom dishes coated with poly-L-lysine (1 mg/ml). The cultures were fixed 36 hours after re-plating and immunostained with antibodies against bIII tubulin and detyrosinated tubulin.
Western Blot
Protein lysates were extracted from transfected cultures using Pierce RIPA Buffer (ThermoFisher Scientific, 89901) supplemented with protease inhibitor cocktail (ThermoFisher Scientific, 78430) and phosphatase inhibitor Cocktail3 (Sigma#P0044-1ML). Total protein concentration in the lysates was measured using BCA protein assay (ThermoFisher Scientific, 23227). 20 mg of proteins was loaded per lane in 4%-15% gradient SDS-PAGE gel (Bio-RAD #456-1084), after which transfer was conducted onto PVDF membranes (Bio-RAD #162-0177) at 4 C for 16-18 hours at 30V. Membranes were then blocked for 1 hour in 5% fat-free milk (Lab Scientific # M0841) in 1xTBS-T (10x TBS Bio-RAD #170-6435). Blots were treated with rabbit anti-tau (tauR1 [43] , 1:2000, Gift from Dr. Nicholas Kanaan from Michigan State University), anti-bIII-tubulin (1:20000; Biolegend#802001), mouse anti-bIII-tubulin (1:20000; Biolegend #801202), rat anti-tyrosinated tubulin (1:500; Millipore, #MAB1864), rabbit anti-detyrosinated tubulin (1:500; Millipore ab3201), or mouse anti-GAPDH (1:5000; abcam#ab8245), followed by appropriate peroxidase-conjugated secondary antibodies. Blots were visualized using Super Signal West Pico kit (ThermoFisher Scientific, 34580). The intensity of the bands on the blots was measured using Image Lab (Bio-Rad).
Live-cell Microscopy EB3-GFP DNA was co-transfected with control scrambled siRNA, tau siRNA or MAP6 siRNA, respectively. Live-cell imaging were conducted 3 days after transfection. Images were captured at an interval of 1 or 2 s for a total of 1-3 minutes using the Zeiss 100X/1.46 planachromat objective. The videos were quantified for the number and velocity of the comets, and kymographs were generated using Zeiss Blue edition software. Figure 1D -(Control = 1 ± 0.05, n = 14; tau siRNA = 1.25 ± 0.07, n = 12; tau siRNA + GFP-tau 4R = 0.922 ± 0.03, n = 15) *, p < 0.05. Figure 1F -(Control = 80% ± 4.5%, n = 14; tau siRNA = 56% ± 3.1%, n = 15) **, p < 0.01. Figure 1P -(DMSO: tau = 100% ± 14%, tyrosinated tubulin = 100% ± 9%, bIII-tubulin = 100% ± 12%, n = 27; Nocodazole: tau = 31% ± 3%, tyrosinated tubulin = 8% ± 0.9%, bIII-tubulin = 45% ± 6%, n = 15).
QUANTIFICATION AND STATISTICAL ANALYSIS
Figure 2
Figures 2C and 2D -tau siRNA (16% ± 4.0%) and MAP6 siRNA (31% ± 8.0%) and show increase in tau expression (129% ± 8.2%) when MAP6 is depleted (n = 5) as well as increase in MAP6 expression (154% ± 2%) when tau is depleted (n = 3) *, p < 0.05 and **, p < 0.01. Figure 2I -(Control = 1 ± 0.1, n = 23; tau siRNA = 2.37 ± 0.31, n = 26) **, p < 0.01. Figure 2J -(Control, R = 23% ± 5% n = 10; tau siRNA, R = 53% ± 5% n = 10) using ImageJ and the Pearson's correlation coefficient is shown. **, p < 0.01. Figure 2Q -(DMSO: Control = 100% ± 14%, n = 20, tau siRNA = 107% ± 16%, n = 20, MAP6 siRNA = 98% ± 21%, n = 20; Nocodazole: Control = 47% ± 6%, n = 22, tau siRNA = 92% ± 8%, n = 22, MAP6 siRNA = 18% ± 4%, n = 23) *, p < 0.05, **, p < 0.01. All data analyses, statistical comparisons, and graphs were generated using Excel (Microsoft) and GraphPad Prism version 7.00 for Mac OsX (GraphPad Software, La Jolla, California, USA, http://www.graphpad.com). Data were confirmed for normality using Shapiro-Wilk's test. Comparisons were performed using a two-tailed t test or one-way ANOVA, with post hoc Tukey test. ''n'' refers to number of neurons quantified in each group. All of the data were presented as mean ± SEM. For all statistical analysis, the mean difference was considered to be significant at or below 0.05 level. All outliers were included in the analysis.
